CA
GMAB icon

Clearstead Advisors’s Genmab GMAB Stock Holding History

Clearstead Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.6K Buy
642
+299
+87% +$7.95K ﹤0.01% 1829
2026
Q1 		$9.2K Sell
343
-334
-49% -$10K ﹤0.01% 1607
2025
Q4 		$20.9K Buy
677
+272
+67% +$8.48K ﹤0.01% 1693
2025
Q3 		$12.4K Buy
405
+334
+470% +$8.14K ﹤0.01% 1848
2025
Q2 		$1.47K Hold
71
– – ﹤0.01% 2381
2025
Q1 		$1.39K Sell
71
-1,277
-95% -$26.8K ﹤0.01% 1952
2024
Q4 		$28.1K Sell
1,348
-311
-19% -$6.83K ﹤0.01% 1293
2024
Q3 		$40.4K Sell
1,659
-243
-13% -$6.5K ﹤0.01% 1250
2024
Q2 		$47.8K Buy
1,902
+1,588
+506% +$45K ﹤0.01% 1173
2024
Q1 		$9.16K Sell
314
-91
-22% -$2.67K ﹤0.01% 1067
2023
Q4 		$12.9K Buy
405
+200
+98% +$6.28K ﹤0.01% 1017
2023
Q3 		$7.23K Buy
+205
New +$7.81K ﹤0.01% 1039
2021
Q4 		– Sell
-1,890
Closed -$83K – 1336
2021
Q3 		$83K Buy
+1,890
New +$84.8K 0.01% 519

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's GMAB Position: Q2 2026 in Review

Clearstead Advisors increased its Genmab (GMAB) stake by 87% in Q2 2026, buying an estimated $7.95K and bringing the position to 642 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Clearstead Advisors first reported a position in GMAB in Q3 2021 and has held it in 13 quarters since. The position peaked at $83K in Q3 2021. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Clearstead Advisors held 642 shares of Genmab worth $17.6K as of Q2 2026.
  • Clearstead Advisors bought 299 Genmab shares in Q2 2026, an estimated $7.95K.
  • Genmab made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1829 holding.
  • Clearstead Advisors first reported a position in Genmab in Q3 2021 and has held it in 13 quarters since.
  • Clearstead Advisors's Genmab position peaked at $83K in Q3 2021.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.